Title
Category
Credits
Event date
Cost
  • Oncology
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
As the treatment paradigm for bladder cancer continuously evolves, all members of the oncology healthcare team must be equipped to evolve with it to ensure optimal patient care. With this evolution comes many questions for the bladder cancer treatment team. Join Drs. Neal Shore, Arjun Balar, Lidia Lopez, and Nurse Joanie Pfahl as they examine the new paradigm of bladder treatment using ICIs, and discuss the important role of each person on the treatment team.
  • Oncology
  • ANCC
  • Participation
$0.00
Nurse and physician expert faculty will discuss the emerging advances in the treatment of chronic lymphocytic leukemia (CLL) with novel agents targeting the B-cell receptor (BCR) pathway, and the latest, top-line safety and efficacy trial data for monotherapy and combination therapy strategies for CLL in first- and later-line settings. Attendees will understand how to differentiate between the different novel agents available with regard to efficacy, adverse event profile, and other relevant clinical factors.
  • Oncology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Click here for activity.
  • Oncology
  • Pulmonology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Medical Moment Two: Expert Insight on Applying the ADAURA Results to Treatment of Early-Stage NSCLC Patients 
  • Oncology
  • Pulmonology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Medical Moment One: Expert Insight on Practical Aspects of Molecular Profiling for Early-Stage NSCLC Cancers 
  • Hematology
  • Oncology
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
01/12/2022
$0.00
This series will review the role of the B-cell receptor pathway in the treatment of B-cell malignancies and explore the latest safety and efficacy data for novel, oral agents such as BTK inhibitors, PI3K inhibitors, and BCL-2 inhibitors.Presented by Creative Educational Concepts, Inc. and accredited by the University of Cincinnati.Supported through independent educational grants from AstraZeneca and Janssen.
  • Neurology
  • Oncology
  • AMA PRA Category 1 Credit™
  • Participation
01/20/2022
$0.00
This educational activity is targeted to pediatric neurosurgeons, neurosurgeons, neuro-oncologists, neuroradiologists, medical oncologists, pediatric hem/onc nurses, and other members of the interprofessional, multidisciplinary neuro-oncology team attending the 2021 AANS/CNS section on Pediatric Neurological Surgery who care for patients with neurofibromatosis type 1 (NF1).
  • Hematology
  • Oncology
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
01/31/2022
$0.00
This series will review the role of the B-cell receptor pathway in the treatment of B-cell malignancies and explore the latest safety and efficacy data for novel, oral agents such as BTK inhibitors, PI3K inhibitors, and BCL-2 inhibitors.Presented by Creative Educational Concepts, Inc. and accredited by the University of Cincinnati.Supported through independent educational grants from AstraZeneca and Janssen.